<li id="4w4yg"></li>
<button id="4w4yg"><input id="4w4yg"></input></button>
<li id="4w4yg"></li>
  • <li id="4w4yg"><source id="4w4yg"></source></li>
  • <strike id="4w4yg"></strike>
    <strike id="4w4yg"><acronym id="4w4yg"></acronym></strike><button id="4w4yg"><dl id="4w4yg"></dl></button>
    <strike id="4w4yg"><acronym id="4w4yg"></acronym></strike>
    <bdo id="4w4yg"></bdo>
    產品展示 / products 您的位置:網站首頁 > 產品展示 > 細胞庫 > 細胞系 > 人非小細胞肺癌細胞NCI-H358
    人非小細胞肺癌細胞NCI-H358

    人非小細胞肺癌細胞NCI-H358

    簡要描述:青旗(上海)生物技術發展有限公司,總部位于上海浦東新區,依托本地高校資源,逐步發展成為以生物技術為主的研發、生產、培訓為一體的綜合化產業平臺,在標準化細胞庫建立及細胞藥物前端模型方面成果顯著。公司生產經營原代細胞、細胞系、ELISA試劑盒、感受態細胞和HPLC檢測等科研產品與服務。我們秉承對用戶負責的態度,以對科研的高度嚴謹,以嚴格的質量控制,為廣大生物醫學科研用戶提供更優質的服務!

    更新時間:2023-06-29

    廠商性質:生產廠家

    瀏覽次數:589

    詳情介紹
    品牌其他品牌貨號BFN60800666
    規格T25培養瓶x1 1.5ml凍存管x2供貨周期現貨
    主要用途僅供科研應用領域醫療衛生,生物產業

    細胞名稱

    人非小細胞肺癌細NCI-H358                  

    img1

    貨物編碼

    BFN60800666

    產品規格

    T25培養x1

    1.5ml凍存x2

    細胞數量

    1x10^6

    1x10^6

    保存溫度

    37

    -198

    運輸方式

    常溫保溫運輸

    干冰運輸

    安全等級

    1

    用途限制

    僅供科研用途                  1類

     

    培養體系

    DMEM高糖培養基Hyclone+10%胎牛血清Gibco+1%雙抗Hyclone

    培養溫度

    37

    二氧化碳濃度

    5%

    簡介

    人非小細胞肺癌細NCI-H358細胞于1981年從一位開始化療之前的患者的腫瘤組織中分離建株。超微結構研究表明細胞質中Clara細胞的特征結構細胞表達主要的肺表面結合蛋SP-A的蛋白RNA。不表SP-BSP-C。他們在軟瓊脂中的克隆形成效率0.83% 

    注釋

    Part of: Cancer Cell Line Encyclopedia (CCLE) project.

    Part of: COSMIC cell lines project.

    Part of: MD Anderson Cell Lines Project.

    Part of: NCI RAS program mutant KRAS cell line panel.

    Doubling time: 38 hours (in RPMI 1640 + 10% FBS), 76 hours (in ACL-3), 60 hours (in ACL-3 + BSA) (PubMed=3940644); 38 hours (ECACC).

    Microsatellite instability: Stable (MSS) (Sanger).

    Omics: Deep exome analysis.

    Omics: Deep phosphoproteome analysis.

    Omics: Deep proteome analysis.

    Omics: Deep RNAseq analysis.

    Omics: DNA methylation analysis.

    Omics: Protein expression by reverse-phase protein arrays.

    Omics: SNP array analysis.

    Omics: Transcriptome analysis.

    Caution: We are not certain that NCI-H358 and NCI-H358M are identical.

    Misspelling: H1358; In PubMed=1311061 table 1.

    STR信息

     Amelogenin:X,YCSF1PO:1112D13S317:812D16S539:1213D18S51:14D19S433:1314D21S11:2830D2S1338:1723D3S1358:1418D5S818:10,12D7S820:1011D8S1179:1314FGA:20,21TH01:6TPOX:89vWA:17

    參考文獻

    PubMed=3940644

    Brower M., Carney D.N., Oie H.K., Gazdar A.F., Minna J.D.

    Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium.

    Cancer Res. 46:798-806(1986)

     

    PubMed=3335022

    Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

    Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

    Cancer Res. 48:589-601(1988)

     

    PubMed=2388294; DOI=10.1093/jnci/82.17.1420

    McLemore T.L., Litterst C.L., Coudert B.P., Liu M.C., Hubbard W.C., Adelberg S., Czerwinski M., McMahon N.A., Eggleston J.C., Boyd M.R.

    Metabolic activation of 4-ipomeanol in human lung, primary pulmonary carcinomas, and established human pulmonary carcinoma cell lines.

    J. Natl. Cancer Inst. 82:1420-1426(1990)

     

    PubMed=2386953

    Gazdar A.F., Linnoila R.I., Kurita Y., Oie H.K., Mulshine J.L., Clark J.C., Whitsett J.A.

    Peripheral airway cell differentiation in human lung cancer cell lines.

    Cancer Res. 50:5481-5487(1990)

     

    PubMed=1311061

    Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D., D'Amico D., Bodner S., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D., Gazdar A.F.

    p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

    Oncogene 7:171-180(1992)

     

    PubMed=1565469

    Bodner S.M., Minna J.D., Jensen S.M., D'Amico D., Carbone D.P., Mitsudomi T., Fedorko J., Buchhagen D.L., Nau M.M., Gazdar A.F., Linnoila R.I.

    Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation.

    Oncogene 7:743-749(1992)

     

    PubMed=8806092; DOI=10.1002/jcb.240630505

    Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P., McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr., Carney D.N., Minna J.D., Mulshine J.L.

    NCI-Navy Medical Oncology Branch cell line data base.

    J. Cell. Biochem. 63 Suppl. 24:32-91(1996)

     

    PubMed=8806101; DOI=10.1002/jcb.240630514

    Lokshin A., Levitt M.L.

    Effect of suramin on squamous differentiation and apoptosis in three human non-small-cell lung cancer cell lines.

    J. Cell. Biochem. 63 Suppl. 24:186-197(1996)

     

    PubMed=9649128; DOI=10.1038/bjc.1998.361

    Yi S., Chen J.-R., Viallet J., Schwall R.H., Nakamura T., Tsao M.-S.

    Paracrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines.

    Br. J. Cancer 77:2162-2170(1998)

     

    PubMed=11030152; DOI=10.1038/sj.onc.1203815

    Modi S., Kubo A., Oie H., Coxon A.B., Rehmatulla A., Kaye F.J.

    Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

    Oncogene 19:4632-4639(2000)

     

    PubMed=11369051; DOI=10.1016/S0165-4608(00)00363-0

    Luk C., Tsao M.-S., Bayani J., Shepherd F., Squire J.A.

    Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization.

    Cancer Genet. Cytogenet. 125:87-99(2001)

     

    PubMed=12068308; DOI=10.1038/nature00766

    Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.

    Mutations of the BRAF gene in human cancer.

    Nature 417:949-954(2002)

     

    PubMed=18083107; DOI=10.1016/j.cell.2007.11.025

    Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., Nardone J., Lee K., Reeves C., Li Y., Hu Y., Tan Z., Stokes M., Sullivan L., Mitchell J., Wetzel R., Macneill J., Ren J.M., Yuan J., Bakalarski C.E., Villen J., Kornhauser J.M., Smith B., Li D., Zhou X., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.

    Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

    Cell 131:1190-1203(2007)

     

    PubMed=19472407; DOI=10.1002/humu.21028

    Blanco R., Iwakawa R., Tang M., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.

    A gene-alteration profile of human lung cancer cell lines.

    Hum. Mutat. 30:1199-1206(2009)

     

    PubMed=20164919; DOI=10.1038/nature08768

    Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.

    Signatures of mutation and selection in the cancer genome.

    Nature 463:893-898(2010)

     

    PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458

    Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

    A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

    Cancer Res. 70:2158-2164(2010)

     

    PubMed=22460905; DOI=10.1038/nature11003

    Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

    The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

    Nature 483:603-607(2012)

     

    PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112

    Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P., Yordy J., Giri U., Peyton M., Fan Y.H., Diao L., Masrorpour F., Shen L., Liu W., Duchemann B., Tumula P., Bhardwaj V., Welsh J., Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L., Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D., Heymach J.V.

    Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

    Cancer Discov. 2:798-811(2012)

     

    PubMed=24135919; DOI=10.1038/ncomms3617

    Balbin O.A., Prensner J.R., Sahu A., Yocum A., Shankar S., Malik R., Fermin D., Dhanasekaran S.M., Chandler B., Thomas D., Beer D.G., Cao X., Nesvizhskii A.I., Chinnaiyan A.M.

    Reconstructing targetable pathways in lung cancer by integrating diverse omics data.

    Nat. Commun. 4:2617-2617(2013)

     

    PubMed=25485619; DOI=10.1038/nbt.3080

    Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.

    A comprehensive transcriptional portrait of human cancer cell lines.

    Nat. Biotechnol. 33:306-312(2015)

     

    PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

    Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

    A landscape of pharmacogenomic interactions in cancer.

    Cell 166:740-754(2016)

     

    PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005

    Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.

    Characterization of human cancer cell lines by reverse-phase protein arrays.

    Cancer Cell 31:225-239(2017)

     

    PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051

    Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W., Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D., Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E., Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C., Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H., McCormick F.

    Differential effector engagement by oncogenic KRAS.

    Cell Rep. 22:1889-1902(2018)

     

    PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

    Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

    An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

    Cancer Res. 79:1263-1273(2019)

     

    PubMed=31068700; DOI=10.1038/s41586-019-1186-3

    Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

    Next-generation characterization of the Cancer Cell Line Encyclopedia.

    Nature 569:503-508(2019)

     

     

    驗收細胞注意事 

    1、收到人非小細胞肺癌細NCI-H358細胞,請查看瓶子是否有破裂,培養基是否漏出,是否渾濁,如有請盡快聯系 

    2、收到人非小細胞肺癌細NCI-H358細胞,如包裝完好,請在顯微鏡下觀察細胞,由于運輸過程中的問題,細胞培養瓶中的貼壁細胞有可能從瓶壁中脫落下來,顯微鏡下觀察會出現細胞懸浮的情況,出現此狀態時,請不要打開細胞培養瓶,應立即將培養瓶置于細胞培養箱里靜 3-5 小時左右,讓細胞先穩定下,再于顯微鏡下觀察,此時多數細胞會重新貼附于瓶壁。如細胞仍不能貼壁,請用臺盼藍染色法鑒定細胞活力,如臺盼藍染色證實細胞活力正常請按懸浮細胞的方法處理 

    3、收到人非小細胞肺癌細NCI-H358細胞后,請鏡下觀察細胞,用恰當方式處理細胞。若懸浮的細胞較多,請離心收集細胞,接種到一個新的培養瓶中。棄掉原液,使用新鮮配制的培養基,使用進口胎牛血清。剛接到細胞,若細胞不多 血清濃度可以加 15%去培養。若細胞迏 80% ,血清濃度還是 10 

    4、收到人非小細胞肺癌細NCI-H358細胞時如無異常情 ,請在顯微鏡下觀察細胞密度,如為貼壁細胞,未超80%匯合度時,將培養瓶中培養基吸出,留 5-10ML 培養基繼續培養:超 80%匯合度時,請按細胞培養條件傳代培養。如為懸浮細胞,吸出培養液1000 /分鐘離 3 分鐘,吸出上清,管底細胞用新鮮培養基懸浮細胞后移回培養瓶 

    5、將培養瓶置 37培養箱中培養,蓋子微微擰松。吸出的培養基可以保存在滅菌過的瓶子里,存放 4冰箱,以備不時之需 

    624 小時后,人非小細胞肺癌細NCI-H358細胞形態已恢復并貼滿瓶壁,即可傳代。(貼壁細胞)將培養瓶里的培養基倒去, 3-5ml(以能覆蓋細胞生長面為準PBS  Hanks液洗滌后棄去。 0.5-1ml 0.25% EDTA 的胰酶消化,消化時間以具體細胞為準,一 1-3 分鐘,不超 5 分鐘。可以放37培養箱消化。輕輕晃動瓶壁,見細胞脫落下來,加 3-5ml 培養基終止消化。用移液管輕輕吹打瓶壁上的細胞,使之*脫落,然后將溶液吸入離心管內離心1000rpm/5min。棄上清,視細胞數量決定分瓶數,一般一傳二,如細胞量多可一傳三,有些細胞不易傳得過稀,有些生長較快的細胞則可以多傳幾瓶,以具體細胞和經驗為準。(懸浮細胞)用移液管輕輕吹打瓶壁,直接將溶液吸入離心管離心即可 

    7、貼壁細 ,懸浮細胞。嚴格無菌操作。換液時,換新的細胞培養瓶和換新鮮的培養液375%CO2 培養。

     

    特別提醒 原瓶中培養基不宜繼續使用,請更換新鮮培養基培養。



    留言框

    • 產品:

    • 您的單位:

    • 您的姓名:

    • 聯系電話:

    • 常用郵箱:

    • 省份:

    • 詳細地址:

    • 補充說明:

    • 驗證碼:

      請輸入計算結果(填寫阿拉伯數字),如:三加四=7




    无码国产色欲XXXXX视频| 日韩乱码人妻无码中文视频| 久久午夜无码鲁丝片| 亚欧无码精品无码有性视频 | 久久亚洲中文字幕精品有坂深雪| 中文字幕精品视频在线| 麻豆亚洲AV永久无码精品久久| 色婷婷综合久久久久中文| 午夜亚洲AV日韩AV无码大全| 最好的中文字幕视频2019| 国模无码人体一区二区 | 人妻丰满熟妇AV无码片| 天堂√最新版中文在线天堂| 久久精品中文字幕无码绿巨人 | 少妇无码一区二区二三区| 色综合久久中文字幕无码| 日韩av无码中文字幕| 无码av中文一二三区| 久久久久亚洲AV无码专区网站| 人妻少妇无码精品视频区| 久久人妻AV中文字幕| 少妇无码AV无码专区线| 无码av免费毛片一区二区| 中文字幕丰满乱子伦无码专区| 无码人妻精品一区二区三区99性| 国产成人无码久久久精品一| 成人无码区免费A片视频WWW| 亚洲伊人成无码综合网| 无码人妻精品中文字幕| 在线中文字幕精品第5页| 日韩中文字幕精品免费一区| 国产亚洲3p无码一区二区| 久久久久久国产精品无码下载| 天堂中文在线最新版| 国产高清无码视频| 日韩午夜福利无码专区a| 日韩精品无码一区二区三区AV | 中文字幕在线视频第一页| 日韩精品无码一区二区中文字幕| 国产精品无码av在线播放| 在线精品无码字幕无码AV|